Pazopanib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pazopanib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
336
Registered trials
462
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Pazopanib Hydrochloride can convert its Small molecule drug profile and FGFR1 x FGFR3 x Flt3L x ITK x LCK x PDGFRα x PDGFRβ x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pazopanib Hydrochloride (query alias: pazopanib) |
|---|---|
| Modality / target | Small molecule drug; FGFR1 x FGFR3 x Flt3L x ITK x LCK x PDGFRα x PDGFRβ x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit; FGFR1 antagonists, FGFR3 antagonists, Flt3L stimulants |
| Highest global status | Approved |
| Originator | GSK Plc |
| Active developers | Novartis Europharm Ltd., GSK Plc, Novartis Pharmaceuticals Corp. |
The MCP disease footprint includes Metastatic Renal Cell Carcinoma, Soft Tissue Neoplasms, Sarcoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07087158 | Phase 2 | Recruiting | 30 | Progression-free Survival (PFS) |
| NCT06895733 | Phase 1/2 | Recruiting | 65 | Objective Response Rate (ORR) |
| NCT07444619 | Phase 1 | Not yet recruiting | 18 | Safety and Adverse Events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
SPARTO: A phase I study of PD-1 inhibitor spartalizumab (PDR001) in combination with low dose of pazopanib in pediatric relapsed/refractory tumors.
Phase 1; n=41; evaluation: Positive. Reported fields: Adverse Event: liver enzymes increase grade > 3 = one patient experienced liver enzymes increase grade > 3 at DL2 ; Adverse Event: liver enzymes increase grade > 3 = one patient experienced liver enzymes increase grade > 3 at DL2 ; Adverse Event: liver enzymes increase grade > 3 = one patient experienced liver enzymes increase grade > 3 at DL2
Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802.
Phase 2; n=120; evaluation: Positive. Reported fields: mPFS = 2.2 month ( 1.5 - 3.8); mPFS = 2.9 month ( 1.3 - 5.3); mPFS = 3.8 month ( 2.3 - 5.2)
Systemic therapy effectiveness in metastatic non-uterine leiomyosarcoma: A decade of real-world outcomes from an Indian cohort
Not Applicable; n=164; evaluation: Negative. Reported fields: -; -; OS = 10.64 Month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pazopanib Hydrochloride addresses Metastatic Renal Cell Carcinoma, Soft Tissue Neoplasms, Sarcoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-02-27 | 青岛百洋医药股份有限公司与北京诺华制药有限公司签署推广协议 | Approved | Financial terms not disclosed |
| 2014-04-22 | GSK completes major three-part transaction with Novartis | Phase 2 | US$16,000.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pdgfr and EGFR inhibitors as viral production enhancersand methods and uses thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of pazopanib and intermediate thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of pazopanib hydrochloride”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
